Dr Raymond Chan is Professor of Cancer Nursing, Metro South Health and Queensland University of Technology. Ray is a NHMRC Investigator and his program of research focuses on optimising models of care and outcomes for cancer survivors. To date, he has attracted >21.5 million (AUD) of research project grants as a chief investigator (>$7.2 Million as CIA) to undertake research in supportive cancer care. Prof Chan is a chief investigator for 4 NHMRC project grants, 1 NHMRC Partnership Grant and 1 NHMRC Fellowship, and has published 120 peer-reviewed articles.

National and State Levels

Ray is a Past President (2015-17) for the Cancer Nurses Society of Australia  He currently serves as Founding Chair/Co-Chair for the Queensland Collaborative for Cancer Survivorship, and Vice-Chair for the Survivorship Group of the Clinical Oncology Society of Australia.

International Level

Ray serves as Chair for the Survivorship Study Group within the Multinational Association for Supportive Care in Cancer and as a Board Director for the International Society of Nurses in Cancer Care.

Recent funded project highlights include:

•  (2021-2025): Optimising Primary Care for Cancer Survivorship. NHMRC (CIA)
• (2020-2024): Implementation of a nurse-enabled, shared-care follow-up model for early Breast cancer survIvorS (The IBIS-Survivorship study). NHMRC (CIA)
• (2020-2023): PROMISE: Patient-Reported Outcome Measures in cancer care: a hybrid effectiveness-Implementation trial to optimise Symptom control and health service Experience. Cancer Council Queensland (CIB) 
• (2020-2022): Partnering with General practitioners to Optimise Survivorship for PatiEnts with Lymphoma: A Phase II randomised controlled trial (The GOSPEL Trial). HIIRO Queensland Health (CIA)
• (2020-2021): Telehealth Cancer-Related Fatigue Clinic Model for Cancer Survivors: A Pilot Randomised Controlled Trial (The TCRF Trial). PA Research Foundation (CIB)
• (2019-2020): ImplEMenting a nurse-coordinated, INtegrated, shared-care model involving specialists and general practitioners in breast cancer post-treatmENT follow-up: a Phase II randomised controlled trial (The EMINENT Trial). Metro South Health (CIA)
• (2017-2018): Financial Toxicity and Symptom Burden in Cancer Survivors. ONS Foundation (CIA)
• (2017-2020): A sequential multiple assignment randomised trial (SMART) of nursing interventions to reduce pain associated with chemotherapy induced peripheral neuropathy. NHMRC (CID)
• (2016-2019): Peripherally InSerted Central catheter Securement: the PISCES Trial. NHMRC (CIC)
• (2014-2017): Development and evaluation of a nurse-led, tailored self-management behavioural intervention for managing distressing symptoms in patients with advanced cancer (The SM2 Study). RBWH Foundation and NHMRC (CIA)
• (2014-2015): Younger women’s wellness after cancer program.  RBWH Foundation (CID)
• (2014): Central venous Access device SeCurement And Dressing Effectiveness in Cancer Care: The CASCADE Trial.  RBWH Foundation (CIA)
• (2013-2016): Improving quality of life in high-risk cancer populations: a randomised trial of a structured intervention for head and neck cancer survivors. NHMRC (CIJ)
• (2012-2013): A double-blind randomised controlled trial of Moogoo Udder Cream® versus aqueous cream for managing radiation-induced skin reactions in patients with cancer.  RBWH Foundation; Office of Health and Medical Research; Cancer Nurses Society of Australia; Moogoo Skincare
• (2011-2014): The RSVP Trial:  Replacement of Intravascular device administration sets after Standard Versus Prolonged use. NHMRC and RBWH Foundation (CIG)
• (2010): Self-management associated with fatigue in patients with advanced cancer. RBWH Foundation, Queensland Nursing Council, Royal College of Nursing Australia (CIA)